Latest Breaking News On - Mondher mahjoubi - Page 5 : comparemela.com

Innate Pharma SA: Innate Pharma: SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

SAR'579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner

SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies Seite 1

08.06.2023 - Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) is pleased to share Sanofi’s news that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of . Seite 1

Innate Pharma SA: Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by

Innate Pharma SA: Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible

Innate Pharma Announces Conference Call and Webcast for Q1 Business Update